Evidence map›Paper›PMID 33614925›Full record

ArticleLaryngoscope investigative otolaryngology2021

Intra-nasal zinc level relationship to COVID-19 anosmia and type 1 interferon response: A proposal.

Ozlem Equils, Klaudi Lekaj, Arthur Wu, Sahar Fattani, Gene Liu, Lothar Rink

Open access · goldAbstract readEditorial
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Zinc pyrithione is a potent inhibitor of PLJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ozlem EquilsMiOra, Public Health Education Foundation California Los Angeles USA.ORCID https://orcid.org/0000-0002-8707-9019
Klaudi LekajMiOra, Public Health Education Foundation California Los Angeles USA.
Arthur WuCedars-Sinai Medical Center Division of Otolaryngology California Los Angeles USA.
Sahar FattaniMiOra, Public Health Education Foundation California Los Angeles USA.ORCID https://orcid.org/0000-0002-8173-8570
Gene LiuCedars-Sinai Medical Center Division of Otolaryngology California Los Angeles USA.
Lothar RinkInstitute of Immunology RWTH Aachen University Hospital Aachen Germany.
Public Health Foundation · USCedars-Sinai Medical Center · USUniversitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anosmia is common among COVID-19 patients and anosmia assessment is proposed to be useful in the early diagnosis and prognosis of patients. Data on the pathogenesis of anosmia during COVID-19 suggest potential olfactory nerve involvement. Zinc is an essential micronutrient that regulates the immune responses, and zinc deficiency is known to induce anosmia and ageusia. We previously proposed that a drop in nasal zinc level is a normal nasal immune response to acute viral infections, including SARS-CoV-2 infection, and play a role in the pathogenesis of anosmia. The drop in the local zinc level in response to SARS-CoV-2 may lead to lower type 1 interferons and shift toward Th2 immune responses; if prolonged, it may lead to increased viral replication and more severe disease. In people who are at risk for baseline systemic zinc deficiency, such as the elderly and those with chronic diseases such as, chronic lung disease, diabetes, cardiovascular disease, and cancer, SARS-CoV-2 infection-induced drop in nasal zinc level may be more severe and prolonged and lead to an insufficient anti-viral nasal immune response and control the spread of the virus systemically and to the lungs. A better understanding of the clinical implications of baseline systemic zinc deficiency on anosmia and nasal immune responses may allow the development of new treatment strategies to slow down or stop the systemic invasion of SARS-CoV-2.

Indexed as

anosmiacomorbidityCOVID‐19deficiencydiabeteselderlyimmune systeminterferonSARSzinc

Identifiers

PMID33614925
PMCPMC7883601
OpenAlexW3113863267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.